U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
Portfolio Pulse from
Akebia Therapeutics has announced the enrollment of the first patient in the VOICE trial for Vafseo, a treatment for CKD patients on dialysis. The trial will compare Vafseo's effectiveness against the current standard of care in terms of mortality and hospitalization.
December 03, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics has initiated the VOICE trial for Vafseo, targeting improved outcomes for CKD patients on dialysis. This could potentially enhance Vafseo's market position if successful.
The initiation of the VOICE trial is a significant step for Akebia Therapeutics as it seeks to demonstrate the efficacy of Vafseo in improving patient outcomes. Successful results could lead to increased adoption and market share, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90